glp-1 and parkinson's disease Some epidemiologic studies have suggested that the risk of is increased among persons with type 2 #Diabetes, with the risk potentially attenuated in those taking glucagon-like peptide-1 (GLP-1) receptor agonists GLP-1 Drugs and Parkinson's Disease:

A Cleveland Clinic analysis of nearly 8,000 patients found that discontinuing semaglutide and tirzepatide did not lead to significant immediate weight regain in clinical practice

J Clin Invest 123 , 22072217, doi:10.1172/JCI66323 (2013)

The absorption advantage is real - IV delivery does provide 100% bioavailability compared to the 20-30% absorption you get from oral supplements

American Journal of Medicine, 133(11S), S12-S22

Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the global collaborative network